Tesamorelin Compounding Access After FDA Panel Endorses 6 Peptides

A clinician I spoke with recently described a shift in how obesity researchers talk about growth hormone-releasing hormone analogs. For years, tesamorelin sat in a narrow lane, FDA-approved only for HIV-associated lipodystrophy. Now, after a recent FDA advisory committee vote on six peptides, the conversation has widened to off-label obesity and even alcohol use disorder. The panel's endorsement does not change the drug's approved indication, but it does reshape the compounding landscape for 503A and 503B pharmacies.

The FDA Panel Vote and What It Actually Means

On March 19, 2025, the FDA's Pharmacy Compounding Advisory Committee voted 10-3 that tesamorelin should be included on a list of bulk drug substances allowed for compounding under section 503A. The vote is part of a broader review of six peptides, including semaglutide base and others. This is not an approval, but a recommendation that the FDA place tesamorelin on the 503A bulks list, which would permit compounding pharmacies to use the raw powder to prepare patient-specific prescriptions when an FDA-approved product is unavailable or not suitable.

The panel considered safety data, clinical need, and the potential for off-label use. A 2023 case report described a patient with non-alcoholic fatty liver disease who showed reduced liver fat on tesamorelin, hinting at broader metabolic effects. The committee's discussion acknowledged that while the evidence for obesity is still emerging, the safety profile in the approved HIV population is well-documented. On an evidence quality scale, the obesity data is a 2 of 3, with small trials and mechanistic plausibility but no large phase 3 studies.

Compounding Access Under 503A and 503B

If the FDA follows the panel's advice, tesamorelin would join a short list of peptides allowed for 503A compounding. Currently, 503B outsourcing facilities can compound tesamorelin only when the FDA-approved product, Egrifta, is in shortage. The panel's vote could open a parallel pathway for 503A pharmacies to compound it without a shortage trigger, provided they have a valid prescription for an individual patient. This distinction matters because 503A pharmacies serve local communities, while 503B facilities ship nationwide.

Cost is a driving factor. Egrifta's list price is around $6,000 per month. Compounded versions from 503A pharmacies might run $200 to $400 per month, depending on the dose. A pharmacy owner I spoke with estimated that raw tesamorelin acetate costs about $48 per vial at scale, though final pricing includes sterility testing and labor. The FDA's recent warning on GLP-1 drugs shows the agency is scrutinizing compounded peptides more closely, so any new access will come with heightened oversight.

Off-Label Obesity and Alcohol Use Disorder Implications

Researchers are exploring tesamorelin for two off-label uses: obesity and alcohol use disorder. A 2022 study (PubMed) found that tesamorelin reduced visceral adipose tissue in obese individuals without HIV, with a mean reduction of 15% over 26 weeks. The mechanism involves growth hormone release, which promotes lipolysis. For alcohol use disorder, preclinical data suggest that growth hormone secretagogues may modulate reward pathways, though human trials are lacking. A 2024 abstract presented at a neuroendocrinology conference reported reduced alcohol craving in a small pilot, but this is a 1 of 3 on evidence quality.

These off-label uses intersect with the compounding debate. If tesamorelin becomes available through 503A pharmacies, clinicians may prescribe it for obesity off-label, much as they do with semaglutide microdosing. The FDA panel discussed this, noting that off-label prescribing is legal but that compounded versions lack the rigorous manufacturing controls of FDA-approved drugs. The safety vs. access debate is central here, as compounded tesamorelin may carry impurity risks that the approved product does not.

Semaglutide and the Broader Peptide Landscape

Semaglutide base was also on the panel's list, though its fate is tied to ongoing shortage determinations. The panel voted 11-2 to include semaglutide base on the 503A bulks list, but the FDA has already signaled that compounding semaglutide may be restricted once shortages resolve. This creates a parallel with tesamorelin: both are peptides with approved products, but tesamorelin's narrower indication and higher cost make compounding more likely to persist. A 503B facility manager noted that semaglutide compounding volume has dropped 40% since the FDA's telehealth prescriber notice last fall, while tesamorelin inquiries have risen.

Other peptides like MOTS-c and BPC-157 were not on the panel's agenda, but their popularity in wellness circles highlights the demand for compounded peptides. Argireline, a cosmetic peptide, and retatrutide, a triple agonist in trials, are also drawing interest. The panel's focus on six specific substances suggests the FDA is prioritizing peptides with existing FDA-approved counterparts, where safety data are clearer.

Who Is Affected and What to Watch Next

Patients with HIV lipodystrophy stand to gain if compounding access lowers costs, but the bigger impact may be on the off-label obesity market. Clinicians in weight-loss clinics are already fielding questions about tesamorelin as an alternative to GLP-1 agonists. A pharmacist in a 503A compounding pharmacy reported a 300% increase in tesamorelin inquiries since the panel vote, though she cautioned that many requests lack a valid medical basis.

The FDA is expected to issue a final rule on the 503A bulks list by late 2025. In the interim, state boards of pharmacy may issue their own guidance. The FDA's guidance on impurity risks for GHRH analogs will likely shape how pharmacies source and test raw materials. For now, the panel's endorsement is a signal that the agency sees a clinical need for compounded tesamorelin, even as it balances safety concerns.

Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.